Devyser LynchFAP is a targeted NGS solution for the analysis of germline variants associated with hereditary colorectal cancer syndromes. The assay enables the detection of SNVs, indels, and CNVs in genes related to Lynch syndrome, familial adenomatous polyposis (FAP), and MUTYH-associated polyposis (MAP), also incorporating a specific LR-PCR for the correct localization of variants in PMS2 versus its pseudogene PMS2CL.

Key Aspects

Detection of SNVs, indels, and CNVs in 10 genes associated with cancer predisposition syndromes: MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, POLE, POLD1, and CTNNB1.
The design also covers the APC 1B promoter, CTNNB1 exon 3, EPCAM exon 9 and 3′ UTR region, and specific defined mutations for POLD1 and POLE.  
Inclusion of a specific Long-range PCR for PMS2, aimed at differentiating variants of the gene from the PMS2CL pseudogene.
Devyser LynchFAP Coverage
Dedicated software: Provides automated and easy-to-use analysis, with efficient variant analysis without the need for bioinformatics expertise.

Clinical applications

The kit is intended for the study of genes associated with hereditary gastrointestinal cancer syndromes, including MLH1, MSH2, MSH6, PMS2, and EPCAM for Lynch syndrome; APC for FAP; MUTYH for MAP; POLD1 and POLE for colon cancer; and CTNNB1, associated with endometrial cancer. 

Intended audience/user

Molecular biology laboratories and research centers with an interest in a targeted evaluation and simplified workflow of genes involved in hereditary cancer syndromes using NGS.

Benefits

Simplified workflow: easy to implement and suitable for laboratories with different sample volume needs.   Ready-to-use reagents, ensuring a reproducible process and reducing the risk of sample mix-up or contamination.     Integration of a specific LR-PCR for PMS2, which allows for more reliable discrimination of true gene variants versus the homologous regions of PMS2CL. Dedicated software that provides fast and intuitive results, without prior bioinformatics knowledge. A specific module is included to evaluate PMS2/PMS2CL gene conversion events.
Devyser LynchFAP Software

Presentation Details

Main reagents
8-A404-8 Devyser LynchFAP 8 tests
Additional reagents
8-A204 Devyser Library Clean

Area:

Hereditary cancer, Molecular Genetics, Targeted study of specific pathologies

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

Franklin by QIAGEN for Somatic Analysis

Advanced cloud-based bioinformatics platform designed for the automated analysis, interpretation, and classification of somatic variants in oncology. Through an integrated environment, the system evaluates clinical evidence in real time, automates classification in accordance with AMP/ASCO/CAP guidelines, and provides access to currently active clinical trials. Detailed description Operating principle End-to-end cloud-based solution for the clinical interpretation…
Qiagen
Next Generation Sequencing (NGS)

SeqOne Genomics – Somatic

SeqOne is a bioinformatics platform for NGS data analysis in precision oncology, designed to detect, prioritise and interpret somatic variants and generate actionable clinical reports from raw sequencing data. It helps laboratories and healthcare professionals accelerate the interpretation of NGS data through an end-to-end workflow. Detailed description Operating principle SeqOne Genomics is a genomic data…
SeqOne
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)